Literature DB >> 9547131

The dopamine hypothesis of schizophrenia: current status, future prospects.

P Willner1.   

Abstract

The dopamine hypothesis of schizophrenia is reviewed in the context of recent advances in dopamine research. These include the following: the discovery that there are several subtypes of dopamine receptor, the recognition that the activity of dopamine neurons is controlled by negative feedback systems; insights into the functions of different subsystems of dopamine neurons; the discovery that different subsystems of dopamine neurons interact with one another; and a growing understanding of the functions and mode of operation of the forebrain regions that the dopamine projections innervate. The paper reviews some of the complexities that the dopamine hypothesis has encountered, and continues to encounter, with a particular focus on three issues: the adequacy of our understanding of neuroleptic drug action, the heterogeneity of schizophrenic symptoms and the paucity of direct evidence to support the hypothesis. It is concluded that schizophrenia does not reflect primary abnormalities of dopamine transmission, but probably does reflect abnormalities in systems that have an intimate interaction with the dopamine system. The primary substrates for schizophrenia will probably be found within the major targets of the ascending dopamine projections: the fronto-striato-pallido-thalamic loops, and the limbic structures, such as amygdala and hippocampus, with which the fronto-striatal system interacts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9547131     DOI: 10.1097/00004850-199711000-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  11 in total

1.  Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.

Authors:  Daniel K Putnam; Jingchun Sun; Zhongming Zhao
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

Review 2.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

3.  Biogenic amines serotonin and dopamine regulate cholangiocyte hyperplastic and neoplastic growth.

Authors:  Gabriel A Frampton; Huang Li; Jonathan Ramirez; Akimuddin Mohamad; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 4.  Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date.

Authors:  Vladimir Lerner; Peter J A McCaffery; Michael S Ritsner
Journal:  CNS Drugs       Date:  2016-04       Impact factor: 5.749

Review 5.  Dopamine partial agonists: a new class of antipsychotic.

Authors:  Jeffrey A Lieberman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.

Authors:  Oliver D Howes; Andrew J Montgomery; Marie-Claude Asselin; Robin M Murray; Paul M Grasby; Philip K McGuire
Journal:  Br J Psychiatry Suppl       Date:  2007-12

7.  A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes.

Authors:  T Ilani; D Ben-Shachar; R D Strous; M Mazor; A Sheinkman; M Kotler; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-09       Impact factor: 11.205

8.  Contrasting effect of prepulse signals on performance of Toxoplasma-infected and Toxoplasma-free subjects in an acoustic reaction times test.

Authors:  Lenka Příplatová; Blanka Sebánková; Jaroslav Flegr
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

Review 9.  Tracing Early Neurodevelopment in Schizophrenia with Induced Pluripotent Stem Cells.

Authors:  Ruhel Ahmad; Vincenza Sportelli; Michael Ziller; Dietmar Spengler; Anke Hoffmann
Journal:  Cells       Date:  2018-09-17       Impact factor: 6.600

Review 10.  Aripiprazole: from pharmacological profile to clinical use.

Authors:  Guido Di Sciascio; Marco Andrea Riva
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-13       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.